Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Dose-escalation Study of Sym004 Monotherapy in Japanese Patients With Advanced Solid Tumors
jRCT2080222258Phase 1Completed
- Sponsor
- Merck Serono
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of futuximab + modotuximab in advanced nonhematological malignancy, Nonhematologic neoplasms and Not applicable, sponsored by Merck Serono. Started Oct 2013; status: completed.
02
Drugs
futuximab + modotuximab
03
Conditions
advanced nonhematological malignancyNonhematologic neoplasmsNot applicable
Beyond the preview
Go deeper on jRCT2080222258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222258.